CRIS Current Research Information System

LAMBERTI, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.952
EU - Europa 1.287
AS - Asia 1.019
AF - Africa 117
OC - Oceania 2
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.380
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.948
SG - Singapore 381
IT - Italia 362
CN - Cina 315
SE - Svezia 230
DE - Germania 175
GB - Regno Unito 159
VN - Vietnam 141
IN - India 98
IE - Irlanda 96
CH - Svizzera 62
TG - Togo 57
BG - Bulgaria 36
FI - Finlandia 33
FR - Francia 32
JO - Giordania 31
CI - Costa d'Avorio 30
ID - Indonesia 28
RU - Federazione Russa 27
NL - Olanda 25
NG - Nigeria 17
BE - Belgio 12
ZA - Sudafrica 9
EE - Estonia 7
UA - Ucraina 7
HK - Hong Kong 6
RO - Romania 4
AT - Austria 3
CA - Canada 3
EG - Egitto 3
ES - Italia 3
IL - Israele 3
LU - Lussemburgo 3
CZ - Repubblica Ceca 2
GE - Georgia 2
HU - Ungheria 2
IR - Iran 2
LB - Libano 2
PK - Pakistan 2
PL - Polonia 2
TR - Turchia 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AU - Australia 1
BD - Bangladesh 1
BR - Brasile 1
CL - Cile 1
GR - Grecia 1
JM - Giamaica 1
KW - Kuwait 1
MK - Macedonia 1
MN - Mongolia 1
NZ - Nuova Zelanda 1
RS - Serbia 1
SA - Arabia Saudita 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
Totale 4.380
Salva come PNG Salva come JPEG
Città #
Singapore 336
Santa Clara 213
Fairfield 190
Chandler 185
Ashburn 176
Southend 141
Boardman 113
Dublin 94
Bologna 83
Princeton 79
Woodbridge 78
Seattle 75
Dong Ket 74
Houston 69
Wilmington 69
Bern 61
Lomé 57
Cambridge 46
Sofia 36
Beijing 35
Amman 31
Abidjan 30
Turin 30
Helsinki 29
Milan 29
Jakarta 28
Ann Arbor 24
Berlin 19
Hyderabad 19
Vicenza 19
New York 18
Redmond 18
Abeokuta 17
Oldenburg 16
Shanghai 16
Guangzhou 15
Westminster 15
Des Moines 14
Florence 14
Breda 11
San Diego 11
Jinan 10
Nanjing 10
Medford 9
Mülheim 9
Brussels 8
Shenyang 8
Wuhan 8
Bremen 7
Falkenstein 7
Los Angeles 7
Chicago 6
Foshan 6
Harbin 6
Olalla 6
Ozzano dell'Emilia 6
Padova 6
Saint Petersburg 6
Valdagno di Trento 6
Zhengzhou 6
Falls Church 5
Hangzhou 5
Tianjin 5
Changsha 4
Haikou 4
Hong Kong 4
Lappeenranta 4
London 4
Naaldwijk 4
Paris 4
Phoenix 4
Qingdao 4
Redwood City 4
Shijiazhuang 4
Verona 4
Xi'an 4
Bühl 3
Calderara di Reno 3
Cologne 3
Den Haag 3
Dongguan 3
Genoa 3
Haltern 3
Imola 3
Moncalieri 3
Moscow 3
Munich 3
Naples 3
Pietrasanta 3
Tel Aviv 3
Washington 3
Wuxi 3
Amsterdam 2
Arezzo 2
Aspremont 2
Bangalore 2
Baoding 2
Boydton 2
Brunswick 2
Bucharest 2
Totale 2.901
Salva come PNG Salva come JPEG
Nome #
Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option? 161
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 135
A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale 134
Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC 127
Concordance between RTOG and EORTC prognostic criteria in low-grade gliomas 125
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 124
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 123
Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors 118
The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy? 108
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 108
New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event 98
Metachronous solitary metastasis to the thyroid gland from squamous cell carcinoma of the lung: a case report and literature review 97
Treatment of advanced gastro‐entero‐pancreatic neuro‐ endocrine tumors: A systematic review and network meta‐analysis of phase iii randomized controlled trials 96
Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor 95
Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study 90
Multimodal strategy in localized merkel cell carcinoma: Where are we and where are we heading? 88
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report 83
The role of clinical and molecular factors in low-grade gliomas: What is their impact on survival? 82
Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer 82
The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers 81
Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study 73
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution 73
Therapeutic options in lung neuroendocrine tumors: between established concepts and new hopes 72
Immunobiology of thymic epithelial tumors: Implications for immunotherapy with immune checkpoint inhibitors 72
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors 71
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) 70
Landscape and future perspectives of immunotherapy in neuroendocrine neoplasia 70
Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study 66
Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors: A National Study From the French Group of Endocrine Tumors (GTE) 66
The functioning side of the pancreas: a review on insulinomas 64
Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications 62
Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors 61
Prophylactic cholecystectomy is not mandatory in patients candidate to the resection for small intestine neuroendocrine neoplasms: a propensity score-matched and cost-minimization analysis 60
Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges 60
An overview on molecular characterization of thymic tumors: Old and new targets for clinical advances 58
Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review 57
Cutaneous Scapular Lesion in an Elderly Woman 53
[68Ga]Ga-DOTANOC Uptake at Pancreatic Head/Uncinate Process: Is It a Persistent Diagnostic Pitfall Over Time? 48
Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study 48
Appendiceal goblet cell carcinoma has marginal advantages from perioperative chemotherapy: a population-based study with an entropy balancing analysis 41
Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors 41
Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study 41
Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis 40
Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management 39
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities 38
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 36
Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab? 36
Lymph node ratio predicts efficacy of postoperative radiation therapy in nonmetastatic Merkel cell carcinoma: A population-based analysis 36
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers with Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels 32
[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective 32
Should we lose hope in adjuvant therapy for neuroendocrine tumors?—In response to: Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit 29
The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis 28
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status 28
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC 26
Role of [18F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors 26
Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease 25
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer 25
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 25
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients 24
Antibody–drug conjugates for lung cancer in the era of personalized oncology 22
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 21
Real-Life Use of [68Ga]Ga-DOTANOC PET/CT in Confirmed and Suspected NETs from a Prospective 5-Year Electronic Archive at an ENETS Center of Excellence: More Than 2000 Scans in More Than 1500 Patients 21
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 21
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 21
Angioside: The role of Angiogenesis and Hypoxia in Lung Neuroendocrine Tumours According to Primary Tumour Location in Left or Right Parenchyma 20
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC 19
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study 19
Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives 19
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma 18
Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3) 18
Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET) 18
ROS1-rearranged Non–small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS) 18
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: Rationale and clinical implication 17
An Update on Appendiceal Neuroendocrine Tumors 17
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 17
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study 17
Non-small-cell lung cancer: how to manage EGFR-mutated disease 17
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer 17
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors 16
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy 16
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 16
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer 15
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer 15
β1600 Q.Clear Digital Reconstruction of [68Ga]Ga-DOTANOC PET/CT Improves Image Quality in NET Patients 15
Non-small-cell lung cancer: how to manage RET-positive disease 14
Challenges and future perspectives for the use of temozolomide in the treatment of SCLC 14
Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer 14
BRAF V600E-mutated large cell neuroendocrine carcinoma responding to targeted therapy: A case report and review of the literature 14
Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort 13
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 13
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1-2 cm 13
Darpp-32 and t-darpp isoform in non-small cell lung cancer (nsclc): Could they drive patients' clinical management and be a therapeutic target? 13
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study 10
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC 10
Title: Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer 9
Safety and Activity of Immune Checkpoint Inhibitors in People Living with HIV and Cancer: A Real-World Report from the Cancer Therapy Using Checkpoint Inhibitors in People Living with HIV-International (CATCH-IT) Consortium 9
Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer 9
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC 8
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 8
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC 8
Totale 4.636
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.468
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.468
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020278 0 0 0 0 0 28 46 79 51 33 26 15
2020/2021520 41 15 3 6 86 25 28 36 58 40 19 163
2021/2022706 12 11 28 30 77 34 15 62 47 63 222 105
2022/20231.229 79 129 50 97 80 87 59 92 244 70 109 133
2023/2024490 36 60 34 40 37 110 24 67 14 32 20 16
2024/20251.282 114 250 264 192 360 102 0 0 0 0 0 0
Totale 4.684